ArticleACS applied bio materials2022
Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells.
Article in ACS applied bio materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review.International journal of nanomedicine · 2026Pooled it
- Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Single-molecule force spectroscopy of ligand-receptor mechanics at extracellular vesicle biointerfaces.Journal of materials chemistry. B · 2026Article
- Cross-Species Analysis of Milk Extracellular Vesicles Reveals a Conserved Innate Core and a Divergent, Human-Specific Adaptive Immune Fraction.International journal of molecular sciences · 2026Article
- Milk derived exosomes sensitize Gefitinib-resistant lung cancer cells to Pemetrexed via CAV1-mediated endocytosis.Drug delivery and translational research · 2026Article
- Milk-derived extracellular vesicles: nutritional significance, nano-delivery potential, and emerging therapeutic applications - an updated review.Food science of animal resources · 2026Review
- Therapeutic Potential of Bovine Colostrum- and Milk-Derived Exosomes in Cancer Prevention and Treatment: Mechanisms, Evidence, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies.Drug design, development and therapy · 2026Review
- Hyaluronic acid-engineered milk extracellular vesicles to target triple negative breast cancer through CD44.Pharmaceutical biology · 2025Article
- The role of 3D culture models and advanced chromatography in exosome research for triple-negative breast cancer.Journal of the Egyptian National Cancer Institute · 2025Review
- Formulation Strategies for Immunomodulatory Natural Products in 3D Tumor Spheroids and Organoids: Current Challenges and Emerging Solutions.Pharmaceutics · 2025Review
- Exploring the Therapeutic Potential of Bovine Colostrum for Cancer Therapies.International journal of molecular sciences · 2025Review
- The Roles of Exosomes in Anti-Cancer Drugs.Cancer medicine · 2025Review
- Milk-derived extracellular vesicles: nature's nanocarriers for drug delivery and therapeutics.Frontiers in pharmacology · 2025Review
- Engineered Perfluorochemical Cancer-Derived Exosomes Loaded with Indocyanine Green and Camptothecin Provide Targeted Photochemotherapy for Effective Cancer Treatment.International journal of nanomedicine · 2025Article
- Assessment of bovine milk exosome preparation and lyophilized powder stability.Journal of extracellular biology · 2024Article
- Review
- Polymeric Micelle-Based Nanogels as Emerging Drug Delivery Systems in Breast Cancer Treatment: Promises and Challenges.Current drug targets · 2024Review
- Article
- Potential therapeutic effects of milk-derived exosomes on intestinal diseases.Journal of nanobiotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Biological nanoparticles, such as exosomes, offer an approach to drug delivery because of their innate ability to transport biomolecules. Exosomes are derived from cells and an integral component of cellular communication. However, the cellular cargo of human exosomes could negatively impact their use as a safe drug carrier. Additionally, exosomes have the intrinsic yet enigmatic, targeting characteristics of complex cellular communication. Hence, harnessing the natural transport abilities of exosomes for drug delivery requires predictably targeting these biological nanoparticles. This manuscript describes the use of two chemical modifications, incorporating a neuropilin receptor agonist peptide (iRGD) and a hypoxia-responsive lipid for targeting and release of an encapsulated drug from bovine milk exosomes to triple-negative breast cancer cells. Triple-negative breast cancer is a very aggressive and deadly form of malignancy with limited treatment options. Incorporation of both the iRGD peptide and hypoxia-responsive lipid into the lipid bilayer of bovine milk exosomes and encapsulation of the anticancer drug, doxorubicin, created the peptide targeted, hypoxia-responsive bovine milk exosomes, iDHRX. Initial studies confirmed the presence of iRGD peptide and the exosomes' ability to target the α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.